178 related articles for article (PubMed ID: 30430389)
1. Integrative Analysis of CD133 mRNA in Human Cancers Based on Data Mining.
Wen GM; Mou FF; Hou W; Wang D; Xia P
Stem Cell Rev Rep; 2019 Feb; 15(1):23-34. PubMed ID: 30430389
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of the cancer stem cell marker CD133 confers a poor prognosis in invasive breast cancer.
Joseph C; Arshad M; Kurozomi S; Althobiti M; Miligy IM; Al-Izzi S; Toss MS; Goh FQ; Johnston SJ; Martin SG; Ellis IO; Mongan NP; Green AR; Rakha EA
Breast Cancer Res Treat; 2019 Apr; 174(2):387-399. PubMed ID: 30554343
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of CD44 in human colon cancer and gastric cancer: Evidence from bioinformatic analyses.
Xia P; Xu XY
Oncotarget; 2016 Jul; 7(29):45538-45546. PubMed ID: 27323782
[TBL] [Abstract][Full Text] [Related]
4. Impact of in vitro driven expression signatures of CD133 stem cell marker and tumor stroma on clinical outcomes in gastric cancers.
Kim TM; Ko YH; Ha SJ; Lee HH
BMC Cancer; 2019 Feb; 19(1):119. PubMed ID: 30717708
[TBL] [Abstract][Full Text] [Related]
5. The roles of CD133 expression in the patients with non-small cell lung cancer.
Wang D; Wen GM; Hou W; Xia P
Cancer Biomark; 2018; 22(3):385-394. PubMed ID: 29758924
[TBL] [Abstract][Full Text] [Related]
6. Notch1 directly induced CD133 expression in human diffuse type gastric cancers.
Konishi H; Asano N; Imatani A; Kimura O; Kondo Y; Jin X; Kanno T; Hatta W; Ara N; Asanuma K; Koike T; Shimosegawa T
Oncotarget; 2016 Aug; 7(35):56598-56607. PubMed ID: 27489358
[TBL] [Abstract][Full Text] [Related]
7. LGR5 and CD133 as prognostic and predictive markers for fluoropyrimidine-based adjuvant chemotherapy in colorectal cancer.
Stanisavljević L; Myklebust MP; Leh S; Dahl O
Acta Oncol; 2016 Dec; 55(12):1425-1433. PubMed ID: 27435662
[TBL] [Abstract][Full Text] [Related]
8. Bone marrow-derived mesenchymal stem cells increase drug resistance in CD133-expressing gastric cancer cells by regulating the PI3K/AKT pathway.
Ji N; Yu JW; Ni XC; Wu JG; Wang SL; Jiang BJ
Tumour Biol; 2016 Nov; 37(11):14637-14651. PubMed ID: 27619680
[TBL] [Abstract][Full Text] [Related]
9. The transcription levels and prognostic values of seven proteasome alpha subunits in human cancers.
Li Y; Huang J; Sun J; Xiang S; Yang D; Ying X; Lu M; Li H; Ren G
Oncotarget; 2017 Jan; 8(3):4501-4519. PubMed ID: 27966459
[TBL] [Abstract][Full Text] [Related]
10. Exploring the clonal evolution of CD133/aldehyde-dehydrogenase-1 (ALDH1)-positive cancer stem-like cells from primary to recurrent high-grade serous ovarian cancer (HGSOC). A study of the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium.
Ruscito I; Cacsire Castillo-Tong D; Vergote I; Ignat I; Stanske M; Vanderstichele A; Ganapathi RN; Glajzer J; Kulbe H; Trillsch F; Mustea A; Kreuzinger C; Benedetti Panici P; Gourley C; Gabra H; Kessler M; Sehouli J; Darb-Esfahani S; Braicu EI
Eur J Cancer; 2017 Jul; 79():214-225. PubMed ID: 28525846
[TBL] [Abstract][Full Text] [Related]
11. Clinical significance of putative markers of cancer stem cells in gastric cancer: A retrospective cohort study.
Chen XL; Chen XZ; Wang YG; He D; Lu ZH; Liu K; Zhang WH; Wang W; Li CC; Xue L; Zhao LY; Yang K; Liu JP; Zhou ZG; Hu JK; Mo XM
Oncotarget; 2016 Sep; 7(38):62049-62069. PubMed ID: 27557490
[TBL] [Abstract][Full Text] [Related]
12. CD133-induced TM4SF5 expression promotes sphere growth via recruitment and blocking of protein tyrosine phosphatase receptor type F (PTPRF).
Kim S; Cho CY; Lee D; Song DG; Kim HJ; Jung JW; Kim JE; Park D; Lee H; Um H; Park J; Choi Y; Kim Y; Nam SH; Lee JW
Cancer Lett; 2018 Dec; 438():219-231. PubMed ID: 30217560
[TBL] [Abstract][Full Text] [Related]
13. Integrative Analysis of HNF1B mRNA in Human Cancers Based on Data Mining.
Nie C; Wang B; Wang B; Lv N; Zhang E
Int J Med Sci; 2020; 17(18):2895-2904. PubMed ID: 33173410
[TBL] [Abstract][Full Text] [Related]
14. [Application of genome-wide genechip for screening and identifying genes related to CD133(+)CD200(+) colorectal cancer stem cells].
Zhang S; Li L; Huang Z; Xin X; Xiao B
Nan Fang Yi Ke Da Xue Xue Bao; 2013 Dec; 33(12):1787-91. PubMed ID: 24369246
[TBL] [Abstract][Full Text] [Related]
15. CD133 in brain tumor: the prognostic factor.
Li B; McCrudden CM; Yuen HF; Xi X; Lyu P; Chan KW; Zhang SD; Kwok HF
Oncotarget; 2017 Feb; 8(7):11144-11159. PubMed ID: 28055976
[TBL] [Abstract][Full Text] [Related]
16. DKK3 attenuates the cytotoxic effect of natural killer cells on CD133
Xia P; Xu XY
Mol Carcinog; 2017 Jul; 56(7):1712-1721. PubMed ID: 28218426
[TBL] [Abstract][Full Text] [Related]
17. A rational approach for cancer stem-like cell isolation and characterization using CD44 and prominin-1(CD133) as selection markers.
Lee YJ; Wu CC; Li JW; Ou CC; Hsu SC; Tseng HH; Kao MC; Liu JY
Oncotarget; 2016 Nov; 7(48):78499-78515. PubMed ID: 27655682
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of stem cell marker CD133 determined by promoter methylation but not by immunohistochemical expression in malignant gliomas.
Wu X; Wu F; Xu D; Zhang T
J Neurooncol; 2016 Apr; 127(2):221-32. PubMed ID: 26757925
[TBL] [Abstract][Full Text] [Related]
19. The clinicopathological parameters significance of CD133 and Nestin in epithelial ovarian cancer: a meta-analysis.
Zhao L; Li J; Liu M; Zhou H; Zou H; Wei Y; Sun K; Li G; Li S; Pang L
Future Oncol; 2017 Dec; 13(28):2555-2570. PubMed ID: 29168665
[TBL] [Abstract][Full Text] [Related]
20. Incomplete radiofrequency ablation promotes the development of CD133
Yuan CW; Wang ZC; Liu K; Liu DJ
Hepatobiliary Pancreat Dis Int; 2018 Oct; 17(5):416-422. PubMed ID: 30262419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
